{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T03:24:30Z","timestamp":1778037870418,"version":"3.51.4"},"reference-count":42,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T00:00:00Z","timestamp":1706313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Vaxart, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>As new SARS-CoV-2 variants continue to emerge and impact communities worldwide, next-generation vaccines that enhance protective mucosal immunity may have a significant impact on productive infection and transmission. We have developed recombinant non-replicating adenovirus serotype 5 (rAd5) vaccines delivered by mucosal administration that express both target antigen and a novel molecular adjuvant within the same cell. Here, we describe the immunogenicity of three unique SARS-CoV-2 rAd5 vaccine candidates and their efficacy following viral challenge in non-human primates (NHPs). Intranasal immunization with rAd5 vaccines expressing Wuhan, or Beta variant spike alone, or Wuhan spike and nucleocapsid elicited strong antigen-specific serum IgG and IgA with neutralizing activity against multiple variants of concern (VOC). Robust cross-reactive mucosal IgA was detected after a single administration of rAd5, which showed strong neutralizing activity against multiple VOC. Additionally, mucosal rAd5 vaccination increased spike-specific IFN-\u03b3 producing circulating T-cells. Upon Beta variant SARS-CoV-2 challenge, all the vaccinated NHPs exhibited significant reductions in viral load and infectious particle shedding in both the nasal passages and lower airways. These findings demonstrate that mucosal rAd5 immunization is highly immunogenic, confers protective cross-reactive antibody responses in the circulation and mucosa, and reduces viral load and shedding after SARS-CoV-2 challenge.<\/jats:p>","DOI":"10.3390\/vaccines12020132","type":"journal-article","created":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T04:57:07Z","timestamp":1706504227000},"page":"132","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Next-Generation Adenoviral Vaccine Elicits Mucosal and Systemic Immunogenicity and Reduces Viral Shedding after SARS-CoV-2 Challenge in Nonhuman Primates"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0933-6737","authenticated-orcid":false,"given":"Sarah N.","family":"Tedjakusuma","sequence":"first","affiliation":[{"name":"Vaxart, Inc., South San Francisco, CA 94080, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin A.","family":"Lester","sequence":"additional","affiliation":[{"name":"Vaxart, Inc., South San Francisco, CA 94080, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena D.","family":"Neuhaus","sequence":"additional","affiliation":[{"name":"Vaxart, Inc., South San Francisco, CA 94080, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0587-2751","authenticated-orcid":false,"given":"Emery G.","family":"Dora","sequence":"additional","affiliation":[{"name":"Vaxart, Inc., South San Francisco, CA 94080, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samanta","family":"Gutierrez","sequence":"additional","affiliation":[{"name":"Vaxart, Inc., South San Francisco, CA 94080, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7730-565X","authenticated-orcid":false,"given":"Molly R.","family":"Braun","sequence":"additional","affiliation":[{"name":"Vaxart, Inc., South San Francisco, CA 94080, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean N.","family":"Tucker","sequence":"additional","affiliation":[{"name":"Vaxart, Inc., South San Francisco, CA 94080, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3478-8751","authenticated-orcid":false,"given":"Becca A.","family":"Flitter","sequence":"additional","affiliation":[{"name":"Vaxart, Inc., South San Francisco, CA 94080, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.medj.2022.09.010","article-title":"Duration of BA.5 neutralization in sera and nasal swabs from SARS-CoV-2 vaccinated individuals, with or without omicron breakthrough infection","volume":"3","author":"Planas","year":"2022","journal-title":"Med"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/s41577-021-00583-2","article-title":"Mucosal vaccines\u2014fortifying the frontiers","volume":"22","author":"Lavelle","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nri1777","article-title":"Mucosal vaccines: The promise and the challenge","volume":"6","author":"Neutra","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1056\/NEJMoa2102214","article-title":"Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant","volume":"384","author":"Madhi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Willett, B.J., Grove, J., MacLean, O.A., Wilkie, C., Logan, N., Lorenzo, G.D., Furnon, W., Scott, S., Manali, M., and Szemiel, A. (2022). The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism. medRxiv, 2022.2001.2003.21268111.","DOI":"10.1101\/2022.01.03.21268111"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Buchan, S.A., Chung, H., Brown, K.A., Austin, P.C., Fell, D.B., Gubbay, J.B., Nasreen, S., Schwartz, K.L., Sundaram, M.E., and Tadrous, M. (2022). Effectiveness of COVID-19 vaccines against Omicron or Delta infection. medRxiv, 2021.2012.2030.21268565.","DOI":"10.1101\/2021.12.30.21268565"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3389\/fimmu.2013.00185","article-title":"Multi-faceted functions of secretory IgA at mucosal surfaces","volume":"4","author":"Corthesy","year":"2013","journal-title":"Front. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Muramatsu, M., Yoshida, R., Yokoyama, A., Miyamoto, H., Kajihara, M., Maruyama, J., Nao, N., Manzoor, R., and Takada, A. (2014). Comparison of antiviral activity between IgA and IgG specific to influenza virus hemagglutinin: Increased potential of IgA for heterosubtypic immunity. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0085582"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Saito, S., Sano, K., Suzuki, T., Ainai, A., Taga, Y., Ueno, T., Tabata, K., Saito, K., Wada, Y., and Ohara, Y. (2019). IgA tetramerization improves target breadth but not peak potency of functionality of anti-influenza virus broadly neutralizing antibody. PLoS Pathog., 15.","DOI":"10.1371\/journal.ppat.1007427"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1172\/JCI132005","article-title":"Immune exclusion by naturally acquired secretory IgA against pneumococcal pilus-1","volume":"130","author":"Binsker","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1128\/JVI.00408-20","article-title":"Potential Role of Nonneutralizing IgA Antibodies in Cross-Protective Immunity against Influenza A Viruses of Multiple Hemagglutinin Subtypes","volume":"94","author":"Okuya","year":"2020","journal-title":"J. Virol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/mi.2011.41","article-title":"Secretory IgA\u2019s complex roles in immunity and mucosal homeostasis in the gut","volume":"4","author":"Mantis","year":"2011","journal-title":"Mucosal Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"eabf1555","DOI":"10.1126\/scitranslmed.abf1555","article-title":"Enhanced SARS-CoV-2 neutralization by dimeric IgA","volume":"13","author":"Wang","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e2315354120","DOI":"10.1073\/pnas.2315354120","article-title":"Conversion of monoclonal IgG to dimeric and secretory IgA restores neutralizing ability and prevents infection of Omicron lineages","volume":"121","author":"Marcotte","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Flitter, B.A., Braun, M.R., and Tucker, S.N. (2022). Drop the Needle; A Temperature Stable Oral Tablet Vaccine Is Protective against Respiratory Viral Pathogens. Vaccines, 10.","DOI":"10.3390\/vaccines10040593"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1473-3099(19)30584-5","article-title":"Efficacy, immunogenicity, and safety of an oral influenza vaccine: A placebo-controlled and active-controlled phase 2 human challenge study","volume":"20","author":"Liebowitz","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e121077","DOI":"10.1172\/jci.insight.121077","article-title":"Safety and immunogenicity of an oral tablet norovirus vaccine, a phase I randomized, placebo-controlled trial","volume":"3","author":"Kim","year":"2018","journal-title":"JCI Insight"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S1473-3099(15)00266-2","article-title":"High titre neutralising antibodies to influenza after oral tablet immunisation: A phase 1, randomised, placebo-controlled trial","volume":"15","author":"Liebowitz","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"eabn6868","DOI":"10.1126\/scitranslmed.abn6868","article-title":"Adenovirus type 5 SARS-CoV-2 vaccines delivered orally or intranasally reduced disease severity and transmission in a hamster model","volume":"14","author":"Langel","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Awasthi, M., Macaluso, A., Myscofski, D., Prigge, J., Koide, F., Noyce, R.S., Fogarty, S., Stillwell, H., Goebel, S.J., and Daugherty, B. (2023). Immunogenicity and Efficacy of TNX-1800, A Live Virus Recombinant Poxvirus Vaccine Candidate, against SARS-CoV-2 Challenge in Nonhuman Primates. Vaccines, 11.","DOI":"10.1101\/2023.09.19.558485"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Flitter, B.A., Lester, C.A., Tedjakusuma, S.N., Dora, E.G., Peinovich, N., Cortese, M.C., Martinez, C.I., Jegede, C.B., Neuhaus, E.D., and Tucker, S.N. (2022). Mucosal Immunization of Cynomolgus Macaques with Adenoviral Vector Vaccine Elicits Neutralizing Nasal and Serum Antibody to Several SARS-CoV-2 Variants. bioRxiv.","DOI":"10.1101\/2022.02.21.481345"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.virol.2004.09.030","article-title":"Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys","volume":"330","author":"McAuliffe","year":"2004","journal-title":"Virology"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Hartman, A.L., Nambulli, S., McMillen, C.M., White, A.G., Tilston-Lunel, N.L., Albe, J.R., Cottle, E., Dunn, M.D., Frye, L.J., and Gilliland, T.H. (2020). SARS-CoV-2 infection of African green monkeys results in mild respiratory disease discernible by PET\/CT imaging and shedding of infectious virus from both respiratory and gastrointestinal tracts. PLoS Pathog., 16.","DOI":"10.1101\/2020.06.20.137687"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41590-020-00835-8","article-title":"Establishment of an African green monkey model for COVID-19 and protection against re-infection","volume":"22","author":"Woolsey","year":"2021","journal-title":"Nat. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"eabe8146","DOI":"10.1126\/scitranslmed.abe8146","article-title":"Single-cell RNA sequencing reveals SARS-CoV-2 infection dynamics in lungs of African green monkeys","volume":"13","author":"Speranza","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41586-020-03041-6","article-title":"Correlates of protection against SARS-CoV-2 in rhesus macaques","volume":"590","author":"McMahan","year":"2021","journal-title":"Nature"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"909910","DOI":"10.3389\/fimmu.2022.909910","article-title":"IgG Anti-Spike Antibodies and Surrogate Neutralizing Antibody Levels Decline Faster 3 to 10 Months After BNT162b2 Vaccination Than After SARS-CoV-2 Infection in Healthcare Workers","volume":"13","author":"Decru","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1473-3099(22)00362-0","article-title":"Immune responses after omicron infection in triple-vaccinated health-care workers with and without previous SARS-CoV-2 infection","volume":"22","author":"Blom","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41422-022-00631-z","article-title":"A pan-sarbecovirus vaccine induces highly potent and durable neutralizing antibody responses in non-human primates against SARS-CoV-2 Omicron variant","volume":"32","author":"Liu","year":"2022","journal-title":"Cell Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"7793","DOI":"10.1128\/JVI.00979-13","article-title":"Recombinant IgA is sufficient to prevent influenza virus transmission in guinea pigs","volume":"87","author":"Seibert","year":"2013","journal-title":"J. Virol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"McMahan, K., Wegmann, F., Aid, M., Sciacca, M., Liu, J., Hachmann, N.P., Miller, J., Jacob-Dolan, C., Powers, O., and Hope, D. (2023). Mucosal boosting enhances vaccine protection against SARS-CoV-2 in macaques. Nature.","DOI":"10.1038\/s41586-023-06951-3"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"100230","DOI":"10.1016\/j.xcrm.2021.100230","article-title":"A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques","volume":"2","author":"Hassan","year":"2021","journal-title":"Cell Rep. Med."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Van Doremalen, N., Lambe, T., Spencer, A., Belij-Rammerstorfer, S., Purushotham, J.N., Port, J.R., Avanzato, V., Bushmaker, T., Flaxman, A., and Ulaszewska, M. (2020). ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques. bioRxiv.","DOI":"10.1101\/2020.05.13.093195"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1056\/NEJMoa0808652","article-title":"Comparative efficacy of inactivated and live attenuated influenza vaccines","volume":"361","author":"Monto","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Madhavan, M., Ritchie, A.J., Aboagye, J., Jenkin, D., Provstgaad-Morys, S., Tarbet, I., Woods, D., Davies, S., Baker, M., and Platt, A. (2022). Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial. EBioMedicine, 85.","DOI":"10.1016\/j.ebiom.2022.104298"},{"key":"ref_36","unstructured":"Altimmune (2023, December 20). Altimmune Announces Update On AdCOVID\u2122 Phase 1 Clinical Trial. 29 June 2021. Available online: https:\/\/ir.altimmune.com\/news-releases\/news-release-details\/altimmune-announces-update-adcovidtm-phase-1-clinical-trial."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Singh, C., Verma, S., Reddy, P., Diamond, M.S., Curiel, D.T., Chintan, P., Jain, M.K., Redkar, S.V., Bhate, A.S., and Gundappa, V. (2023). Immunogenicity and Tolerability of BBV154 (iNCOVACC\u00ae), an Intranasal SARS-CoV-2 Vaccine, Compared with Intramuscular Covaxin\u00ae in Healthy Adults: A Randomised, Open-Label, Phase 3 Clinical Trial. Lancet, preprint.","DOI":"10.2139\/ssrn.4342771"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Jin, L., Tang, R., Wu, S., Guo, X., Hou, L., Chen, X., Zhu, T., Gou, J., Huang, H., and Zhong, J. (2022). Antibody Persistence and Safety through 6 Months after Heterologous Orally Aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously. medRxiv.","DOI":"10.1101\/2022.07.26.22278072"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"7251","DOI":"10.1038\/s41467-021-27202-x","article-title":"Increased transmissibility of SARS-CoV-2 lineage B.1.1.7 by age and viral load","volume":"12","author":"Lyngse","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e868","DOI":"10.1542\/peds.2005-1301","article-title":"A pilot study of the effectiveness of a school-based influenza vaccination program","volume":"116","author":"King","year":"2005","journal-title":"Pediatrics"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"6794","DOI":"10.1016\/j.vaccine.2012.09.018","article-title":"The role of nasal IgA in children vaccinated with live attenuated influenza vaccine","volume":"30","author":"Ambrose","year":"2012","journal-title":"Vaccine"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1038\/s41467-023-37715-2","article-title":"Booster with Ad26.COV2.S or Omicron-adapted vaccine enhanced immunity and efficacy against SARS-CoV-2 Omicron in macaques","volume":"14","author":"Solforosi","year":"2023","journal-title":"Nat. Commun."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/2\/132\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:50:20Z","timestamp":1760104220000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/2\/132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,27]]},"references-count":42,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["vaccines12020132"],"URL":"https:\/\/doi.org\/10.3390\/vaccines12020132","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,27]]}}}